GlassScriptPhysician profile
Emily A Heather
NPI 1780314922
$3,483.76
in general payments reported to CMS, 2019-2025
26 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,978 · 2024: $1,355 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,483.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $365.24 | 2023-2024 | |
| Amgen INC. | $364.21 | 2023-2024 | Evenity, Repatha, Otezla |
| Astellas Pharma US INC | $303.22 | 2023-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $255.24 | 2023-2024 | |
| Glaxosmithkline, LLC. | $226.73 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $207.34 | 2023-2024 | Caplyta |
| Lilly USA, LLC | $205.17 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $185.71 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Dexcom, INC. | $157.41 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $156.91 | 2023-2024 | |
| Madrigal Pharmaceuticals | $134.83 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.36 | 2023-2024 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $124.85 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $122.29 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $121.34 | 2023-2024 | Xarelto, Spravato |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $76.96 | 2023-2024 | Quviviq |
| Amneal Pharmaceuticals LLC | $67.05 | 2023-2024 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.32 | 2023-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $53.92 | 2023-2024 | |
| Esperion Therapeutics, INC. | $33.59 | 2023-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $33.24 | 2023-2024 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Ani Pharmaceuticals, INC. | $25.47 | 2023 | Purified Cortrophin Gel |
| Cequr Corporation | $21.86 | 2024 | Cequr Simplicity |
| Alvogen INC | $19.53 | 2023 | Teriparatide |
| Grifols USA, LLC | $16.08 | 2023 | Prolastin-C Liquid |
| Nestle Healthcare Nutrition INC. | $14.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Heather listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.